Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RubaXX Mono
- Development stage
- Unknown
- Lead developer
- PharmaSGP
- Administration
- Oral
01
Overview
RubaXX Mono is an approved homeopathic over-the-counter (OTC) medicine developed by PharmaSGP for the treatment of rheumatic pain in bones, joints, tendons, and muscles, as well as the consequences of injuries and overexertion. Formulated as an oral tablet, its active ingredient is Rhus toxicodendron (also known as Toxicodendron quercifolium) at a D6 homeopathic dilution (Rhus tox Trit. D6). It is marketed in Germany and other European countries as a natural, well-tolerated alternative to chemical painkillers, with no known severe side effects or drug interactions.
- Brand names
- RubaXX MONORubaXX Mono Tabletten
- Other names
- Rhus toxicodendron Trit. D6Toxicodendron quercifolium Trit. D6
Beyond the preview
Go deeper on RubaXX Mono.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RubaXX Mono.